Rapamycin has been shown to extend lifespan in numerous model organisms including
mice, with the most dramatic longevity effects reported in females. However, little is known …

Even in healthy aging, cardiac morbidity and mortality increase with age in both mice and
humans. These effects include a decline in diastolic function, left ventricular hypertrophy …

Aging is a major risk factor for a large number of disorders and functional impairments.
Therapeutic targeting of the aging process may therefore represent an innovative strategy in …

Inhibition of the mTOR (mechanistic target of rapamycin) signaling pathway by the FDA-
approved drug rapamycin promotes life span in numerous model organisms and delays age …

The FDA approved drug rapamycin increases lifespan in rodents and delays age-related
dysfunction in rodents and humans. Nevertheless, important questions remain regarding the …

Aging can not only shorten a healthy lifespan, but can also lead to multi-organ dysfunction
and failure. Anti-aging is a complex and worldwide conundrum for eliminating the various …

The evolutionarily conserved target of rapamycin (TOR) signaling controls growth,
metabolism, and aging. In the first robust demonstration of pharmacologically-induced life …

Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest
experimental support to date as a potential anti-aging therapeutic in mammals. Unlike many …

In 2009, rapamycin was reported to increase the lifespan of mice when implemented later in
life. This observation resulted in a sea-change in how researchers viewed aging. This was …

Chronic caloric restriction (CR) and rapamycin inhibit the mechanistic target of rapamycin
(mTOR) signaling, thereby regulating metabolism and suppressing protein synthesis …